Frontiers in Oncology (Aug 2021)
Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches
- Giulia Marvaso,
- Giulia Marvaso,
- Giulia Corrao,
- Giulia Corrao,
- Mattia Zaffaroni,
- Matteo Pepa,
- Matteo Augugliaro,
- Stefania Volpe,
- Stefania Volpe,
- Gennaro Musi,
- Gennaro Musi,
- Stefano Luzzago,
- Francesco Alessandro Mistretta,
- Elena Verri,
- Maria Cossu Rocca,
- Matteo Ferro,
- Giuseppe Petralia,
- Giuseppe Petralia,
- Franco Nolè,
- Ottavio De Cobelli,
- Ottavio De Cobelli,
- Roberto Orecchia,
- Barbara Alicja Jereczek-Fossa,
- Barbara Alicja Jereczek-Fossa
Affiliations
- Giulia Marvaso
- Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Giulia Marvaso
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Giulia Corrao
- Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Giulia Corrao
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Mattia Zaffaroni
- Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Matteo Pepa
- Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Matteo Augugliaro
- Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Stefania Volpe
- Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Stefania Volpe
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Gennaro Musi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Gennaro Musi
- Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Stefano Luzzago
- Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Francesco Alessandro Mistretta
- Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Elena Verri
- Department of Medical Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Maria Cossu Rocca
- Department of Medical Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Matteo Ferro
- Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Giuseppe Petralia
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Giuseppe Petralia
- Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Franco Nolè
- Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Ottavio De Cobelli
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Ottavio De Cobelli
- Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Roberto Orecchia
- Scientific Directorate, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Barbara Alicja Jereczek-Fossa
- Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Barbara Alicja Jereczek-Fossa
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- DOI
- https://doi.org/10.3389/fonc.2021.732766
- Journal volume & issue
-
Vol. 11
Abstract
Various definitions are currently in use to describe high-risk prostate cancer. This variety in definitions is important for patient counseling, since predicted outcomes depend on which classification is applied to identify patient’s prostate cancer risk category. Historically, strategies for the treatment of localized high-risk prostate cancer comprise local approaches such as surgery and radiotherapy, as well as systemic approaches such as hormonal therapy. Nevertheless, since high-risk prostate cancer patients remain the group with higher-risk of treatment failure and mortality rates, nowadays, novel treatment strategies, comprising hypofractionated-radiotherapy, second-generation antiandrogens, and hadrontherapy, are being explored in order to improve their long-term oncological outcomes. This narrative review aims to report the current management of high-risk prostate cancer and to explore the future perspectives in this clinical setting.
Keywords
- high risk prostate cancer
- personalized medicine
- hadrontherapy
- narrative review
- second-generation antiandrogens
- iPARP treatment
